Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell L

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. META
8. IMNN
9. NAVN
10. NVDA

Go back to Results of Phase 1a/1b Study of AbbVie's Investigational Medicine Rovalpituzumab Tesirine (Rova-T) Showed Overall Response Rate of 39 Percent in Pretreated Patients with Biomarker-Defined Small Cell L
AbbVie (NYSE: ABBV) Delayed: 230.01 --0 (-0%)
Previous Close $230.01    52 Week High $68.12 
Open $230.01    52 Week Low $50.71 
Day High $230.01    P/E 49.89 
Day Low $230.01    EPS $4.61 
Volume 16,752